Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: A multicenter study from Korea

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 1, 2012, Pages 70-75

  Lee, Ho Sup ^a   Park, Lee Chun ^a   Lee, Eun Mi ^a   Lee, Shin Jun ^a   Shin, Seong Hoon ^a   Im, Hana ^a   Do, Kil Min ^a   Kim, Eeon Jin ^a   Ye, Byeong Jin ^a   Song, Moo Kon ^b   Kim, Sung Hyun ^c   Lee, Sang Min ^d   Lee, Won Sik ^d   Kim, Yang Soo ^a  

^a Kosin University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

Essential thrombocythemia; Incidence rate; Risk factors; Thrombohemorrhagic events

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE; GENE MUTATION; HEART INFARCTION; HUMAN; INCIDENCE; INFORMATION PROCESSING; JAK2 GENE; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MULTIVARIATE ANALYSIS; PERIPHERAL ISCHEMIA; RETROSPECTIVE STUDY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOSIS; UNIVARIATE ANALYSIS; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HUMANS; INCIDENCE; JANUS KINASE 2; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TIME FACTORS; YOUNG ADULT;

EID: 84863138288     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.10.002     Document Type: Article

References (34)

1. A. Tefferi, S. Murphy Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management Blood Rev 15 2001 121 131 (Pubitemid 32999197)
2. T. Barbui Indications for lowering platelet numbers in essential thrombocythemia Semin Hematol 40 2003 22 25 (Pubitemid 36403120)
3. A. Tefferi, J.W. Vardiman Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 2008 14 22
4. P.A. Beer, A.R. Green Pathogenesis and management of essential thrombocythemia Hematology 2009 2009 621 628
5. S. Cortelazzo, P. Viero, G. Finazzi Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia J Clin Oncol 8 1990 556 562 (Pubitemid 20087557)
6. A. Tefferi, N. Gangat, A. Wolanskyj The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia Blood 109 2007 4105 (Pubitemid 46641767)
7. G. Finazzi, T. Barbui Risk-adapted therapy in essential thrombocythemia and polycythemia vera Blood Rev 19 2005 243 252 (Pubitemid 40814453)
8. C. Besses, F. Cervantes, A. Pereira Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients Leukemia 13 1999 150 154 (Pubitemid 29092645)
9. R. Landolfi, L. Di Gennaro, T. Barbui Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood 109 2007 2446 2452 (Pubitemid 46425887)
10. T. Barbui, A. Carobbio, A. Rambaldi Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114 2009 759 763
11. A. Carobbio, G. Finazzi, V. Guerini Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status Blood 109 2007 2310 2313 (Pubitemid 46425868)
12. A.M. Vannucchi, E. Antonioli, P. Guglielmelli Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia Blood 112 2008 844 847
13. P.J. Campbell, D. Bareford, W.N. Erber Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy J Clin Oncol 27 2009 2991 2999
14. M.A. Elliott, A. Tefferi Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia Br J Haematol 128 2005 275 290 (Pubitemid 40216149)
15. G. Finazzi, T. Barbui How I treat patients with polycythemia vera Blood 109 2007 5104 5111 (Pubitemid 46890524)
16. G. Birgegard Long-term management of thrombocytosis in essential thrombocythaemia Ann Hematol 88 2009 1 10
17. T. Barbui, G. Finazzi When and how to treat essential thrombocythemia N Engl J Med 353 2005 85 86 (Pubitemid 41007812)
18. C.S. Chim, Y.L. Kwong, A.K. Lie Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia Arch Intern Med 165 2005 2651 2658 (Pubitemid 41785064)
19. K. Dan, T. Yamada, Y. Kimura Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group Int J Hematol 83 2006 443 449 (Pubitemid 44756798)
20. Y.M. Seol, Y.J. Choi, K.W. Lee The efficacy and adverse effect of hydroxyurea as compared with anagrelide in essential thrombocythemia Korean J Hematol 43 2008 83 88
21. G. Barosi, G. Birgegard, G. Finazzi Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference Blood 113 2009 4829 4833
22. A. Tefferi, M. Elliott Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F Semin Thromb Hemost 33 2007 313 320 (Pubitemid 46878103)
23. A. Carobbio, E. Antonioli, P. Guglielmelli Leukocytosis and risk stratification assessment in essential thrombocythemia J Clin Oncol 26 2008 2732 2736
24. F. Radaelli, M. Colombi, R. Calori Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia Hematol Oncol 25 2007 115 120 (Pubitemid 47507878)
25. C.N. Harrison, P.J. Campbell, G. Buck Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 2005 33 45 (Pubitemid 41007805)
26. P.J. Campbell, L.M. Scott, G. Buck Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study Lancet 366 2005 1945 1953 (Pubitemid 41713984)
27. S.M. Bang, J.S. Lee, J.Y. Ahn Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation Thromb Haemost 101 2009 547 551
28. G. Finazzi, A. Rambaldi, V. Guerini Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status Haematologica 92 2007 135 136 (Pubitemid 46232672)
29. B. Cheung, D. Radia, P. Pantelidis The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia Br J Haematol 132 2006 244 245 (Pubitemid 43381559)
30. E. Antonioli, P. Guglielmelli, A. Pancrazzi Clinical implications of the JAK2 V617F mutation in essential thrombocythemia Leukemia 19 2005 1847 1849 (Pubitemid 41486170)
31. A.P. Wolanskyj, T.L. Lasho, S.M. Schwager JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance Br J Haematol 131 2005 208 213 (Pubitemid 43899687)
32. E. Arellano-Rodrigo, A. Alvarez-Larran, J.C. Reverter Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status Haematologica 91 2006 169 175
33. A. Falanga, M. Marchetti, D. Balducci Distinct hemostatic profile of leukocytes in essential thrombocythemia (ET) carrying the JAK2 V617F mutation ASH Annual Meeting Abstracts 106 2005 378
34. M. Speletas, E. Katodritou, C. Daiou Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders Leuk Res 31 2007 1053 1062